Key result
Dabigatran was associated with numerically reduced major bleeding (0.26 vs. 0.90 per 100 patient-years) and all-cause death compared to vitamin K antagonists in Eastern European patients with atrial fibrillation.
Why the study?
It was unknown whether patients in Eastern Europe with newly diagnosed AF at risk of stroke benefit from treatment with dabigatran versus VKA.
Does dabigatran improve 3-year cardiovascular outcomes and reduce bleeding compared to vitamin K antagonists in Eastern European patients with newly diagnosed atrial fibrillation?
Cohort (n=1,341)
Yes
Does dabigatran improve 3-year cardiovascular outcomes and reduce bleeding compared to vitamin K antagonists in Eastern European patients with newly diagnosed atrial fibrillation?
Absolute Event Rate: 0.26% vs 0.9%
In Eastern European patients with newly diagnosed atrial fibrillation, dabigatran was associated with numerically lower rates of major bleeding, all-cause death, and a cardiovascular composite compared to vitamin K antagonists over 3 years.
No takes yet. Share an insight, caveat, or question.
May support dabigatran preference in Eastern European AF; leaves open need for randomized confirmation.
Bergler‐Klein et al. (2023) conducted a cohort in Atrial Fibrillation (n=1,341). Dabigatran vs. Vitamin K Antagonists was evaluated on Major bleeding (incidence rate per 100 patient-years). Dabigatran was associated with numerically reduced major bleeding (0.26 vs. 0.90 per 100 patient-years) and all-cause death compared to vitamin K antagonists in Eastern European patients with atrial fibrillation.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: